The global single-use bioreactors market size is expected to reach a valuation of USD 18.9 billion by 2033. A valuation of USD 4.5 billion is anticipated for the market by the end of 2023. It is likely to witness a considerable CAGR of 15.4% in the forecast period 2023 to 2033.
The market for single-use bioreactors is set to create an absolute dollar opportunity of USD 14.4 billion in the review period. It stood at a valuation of USD 3.9 billion in 2022.
Traditional stainless-steel bioreactors require costly and laborious cleaning & sterilization procedures, which are not necessary with single-use bioreactors. Due to lower personnel, maintenance, and downtime expenses, several biotech businesses and research organizations might find them to be more cost-effective.
Single-use bioreactors provide more production scale flexibility. They are simple to modify for diverse batch sizes. Hence, they might enable businesses to react swiftly to shifts regarding demand or research requirements.
Single-use bioreactors can decrease the time needed for equipment preparation due to the absence of sanitation and sterilization procedures. They also offer the simplicity of setup, which might result in shorter turnaround times and higher output.
As single-use bioreactors are disposable, there is less chance of batch contamination. This is especially important for producing delicate goods such as vaccinations, biological products, and cell treatments.
The biopharmaceutical sector is becoming more and more concerned with environmental effect mitigation and sustainability. Compared to conventional stainless-steel bioreactors, single-use bioreactors emit less wastewater and utilize fewer resources. These features are expected to make them a more environmentally responsible choice.
Single-use bioreactor technology has advanced, resulting in better performance and higher-quality output. This development is set to surge technology confidence and encourage future use.
With more pharmaceuticals being developed and more biologic therapies receiving approval, the global biopharmaceutical business has been continuously expanding. Need for bioreactors, including single-use systems, might increase as a result of this expansion.
Regulatory bodies such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have become more receptive to these bioreactors. This is attributed to the benefits and safety of single-use bioreactors when employed in the manufacturing process.
Single-use bioreactors are disposed of after use, so there is little danger of cross-contamination between batches. This would help to raise the safety of the final product and lower the possibility of batch failure backed by contamination.
| Attributes | Key Insights |
|---|---|
| Single-use Bioreactors Market Estimated Size (2023E) | USD 4.5 billion |
| Projected Market Valuation (2033F) | USD 18.9 billion |
| Value-based CAGR (2023 to 2033) | 15.4% |
| United States Value-based CAGR (2023 to 2033) | 15.3% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global single-use bioreactors market is expected to witness a CAGR of 15.4% in the forecast period. It grew at a steady CAGR of 16.7% in the historical period between 2018 and 2022.
In recent years, pharmaceutical and biotechnology sectors have placed a growing emphasis on supply chain resilience. Manufacturing and delivery of vital medications & therapies can be severely hampered by problems with the supply chain.
Several issues could be observed during the epidemic, natural catastrophes, or geopolitical events. Single-use bioreactors have become an effective way to improve supply chain resilience in this situation for a number of reasons.
Traditional stainless-steel bioreactors require rigorous cleaning, sterilization, and validation procedures. But, single-use bioreactors are pre-sterilized, pre-assembled, and provide ready-to-use. This would shorten lead times and make inventory management simpler while streamlining the logistics of purchasing & deploying bioreactors.
Single-use bioreactors provide quick switchovers and rapid bioprocess start-ups as no cleaning and validation activities are needed in between batches. Due to their flexibility, biopharmaceutical companies might swiftly respond to changes in demand. They can further modify production schedules and deal with unforeseen supply chain difficulties.
There is also no chance of cross-contamination between different production runs or batches as single-use bioreactors are thrown away. For the safety and quality of delicate biopharmaceutical products, this is set to become very important.
Single-use bioreactors have the capacity to scale for different batch sizes, which might make it simpler to change production volumes in response to demands. Additionally, they make it easy to transfer technologies between several manufacturing facilities. They might hence allow businesses to expand their production capacities and reduce supply chain risks associated with a single location.
With third-party contract development and manufacturing organizations (CDMOs), single-use bioreactors make outsourcing & contract manufacturing arrangements easier. Due to their increased ability to use outside resources to supplement their internal skills, businesses are less dependent on a single site or provider. Owing to the aforementioned factors, single-use bioreactor demand might expand.
The United Kingdom single-use bioreactors market is projected to record a CAGR of 15.1% in the assessment period. It is anticipated to top a valuation of USD 669.9 million by 2033.
The United Kingdom government has provided incentives and financing for life sciences research & development to help the biopharmaceutical sector. Such regulations might incentivize biopharma firms to invest in cutting-edge equipment. Hence, investments in single-use bioreactors can rise to improve production and maintain competitiveness on the international market.
The United Kingdom has also been exploring individualized healthcare approaches, wherein customized treatments are created based on unique patient features. Single-use bioreactors might support the needs of personalized treatment by enabling fewer batches and more individualized output.
In July 2023, for instance, to ensure that a greater number of patients can benefit from personalized cancer treatments, the United Kingdom government inked a long-term partnership deal with BioNTech. The latter had previously created a world-leading COVID-19 vaccine with Pfizer.
It comprises clinical trials conducted in the United Kingdom with the goal of treating patients by using precision immunotherapies. These would help activate the immune system to detect and destroy cancer cells. By 2030, it is intended to give up to 10,000 sufferers access to individualized care.
BioNTech intends to establish new laboratories in Cambridge, with a projected workforce of more than 70 highly experienced scientists. It also aims to develop a brand-new national center for the United Kingdom to assist in the delivery of this research.
China single-use bioreactors market is likely to create an absolute dollar opportunity of USD 3.3 billion in the review period. It recorded a CAGR of 16.5% in the historical period.
Medical and biopharmaceutical sectors in China have expanded significantly in recent years. Increasing manufacturing of biological products, immunizations, and other treatments is set to aid demand. Need for sophisticated bioprocessing technology such as single-use bioreactors might hence skyrocket in China.
In the global biopharmaceutical sector, China has grown to be a significant player. Single-use bioreactors can offer benefits in terms of effectiveness, versatility, and reduced contamination risk. This is projected to help achieve international quality standards and increase exports.
Biologic medication development has accelerated in China. Single-use bioreactors might make it possible to produce these complicated medications more successfully. They are set to help in freeing up businesses to concentrate on developing cutting-edge cures for diverse diseases.
The initial dose of adalimumab replica biological in China was released in January 2020 by Bio-Thera Solutions. The medication will be sold under the name Qletli. It is capable of alleviating plaque psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Such new product launches are expected to open the door to lucrative opportunities.
Based on product, the single-use bioreactor systems segment is anticipated to register a CAGR of 15.3% from 2023 to 2033. It grew at a decent CAGR of 16.5% between 2018 and 2022.
Compared to conventional stainless-steel bioreactors, single-use bioreactors need less time for facility design, installation, and commissioning. This acceleration might make it possible for biopharmaceutical firms to launch their products more quickly, giving patients faster access to treatments that could save their lives.
Due to their disposable nature, single-use bioreactors reduce the possibility of cross-contamination between batches. This feature would help to lower the possibility of expensive batch failures, which is crucial when generating delicate and high-value biopharmaceuticals.
Single-use bioreactors might also make it possible for businesses to manufacture goods as-needed and generate smaller batches of goods. This flexibility is useful for managing tailored treatments or fast adjusting to shifts in consumer expectations.
For instance, in July 2021, Cytiva and Pall Corporation, both subsidiaries of Danaher, announced that they would surge the production of goods & services. This will be mainly done for international life sciences clients as part of a continuing strategic expansion plan.
The already-in-progress investment is a boost to previously planned investments. It includes new sites and factory expansions. It also comes after five purchases the corporations have made in 2021.
In terms of type, the stirred-tank SUB segment is expected to witness a CAGR of 15.2% in the evaluation period. It showcased a considerable CAGR of 16.4% in the historical period.
With an increasing need for monoclonal antibodies, vaccinations, and other biopharmaceutical goods, the biologics sector is still growing. Stirred-tank SUBs are expected to be widely used as they are highly suited for producing these intricate molecules on a big scale.
Continuous bioprocessing, which has benefits including shorter production times, higher productivity, and better product quality, relies heavily on stirred-tank SUBs. Need for SUBs might surge as continuous production gains popularity in the biopharmaceutical sector.
Stirred-tank SUBs are often created with premium components and exact engineering. They can help in guaranteeing reliable and repeatable bioprocessing outcomes. Companies are under pressure to select dependable SUBs for their production processes owing to their concentration on quality assurance and regulatory compliance.
Manufacturers have also been overcoming earlier shortcomings and enhancing performance by continuously advancing stirred-tank SUB technology. Increasing need for these bioreactors is a result of developments in sensor technology, digitization, and data analytics.
In comparison to conventional stainless-steel bioreactors, stirred-tank SUBs use less water and energy. Hence, it might lead to more environmentally friendly bioprocessing. SUBs are a set to be a desirable option backed by their eco-friendly features as firms place increasing importance on environmental concerns.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Leading single-use bioreactors manufacturers might invest heavily in research and development to continuously improve their technology. They can focus on enhancing performance, scalability, and compatibility with different cell types, allowing for more efficient and flexible bioprocessing.
Key players would often form partnerships and collaborations with biopharmaceutical companies, contract manufacturing organizations (CMOs), and research institutions. These alliances can facilitate technology sharing, co-development of customized solutions, and expansion of product offerings to address a broader range of applications.
Mergers and acquisitions might play a crucial role in consolidating the market and acquiring complementary technologies or expertise. Key players would strategically acquire smaller companies or start-ups with innovative technologies to strengthen their product portfolios.
Top companies would further invest in customer support and training services to ensure efficient adoption & use of single-use bioreactors. They would provide technical assistance, application support, and training programs to help customers maximize the benefits of their products.
For instance,
| Attribute | Details |
|---|---|
| Estimated Market Size (2023) | USD 4.5 billion |
| Projected Market Valuation (2033) | USD 18.9 billion |
| Value-based CAGR (2023 to 2033) | 15.4% |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Value (USD billion) |
| Segments Covered | Product, Type, End Use, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; Middle East and Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Nordics, Czech Republic, Poland, Romania, Hungary, China, Japan, South Korea, India, Association of Southeast Asian Nations, Australia & New Zealand, Kingdom of Saudi Arabia, United Arab Emirates, Türkiye, Saudi Arabia, Algeria, Egypt, Morocco |
| Key Companies Profiled | Applikon Biotechnology BV; Cellexus Ltd.; Celltainer Biotech B.V.; Cesco Bioengineering Co. Ltd.; Danaher Corporation |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
The single-use bioreactors market is valued at USD 4.5 billion in 2023.
The growth potential of the single-use bioreactors market is 15.4% CAGR through 2033.
Surging demand for personalized treatment and the launch of new biologics are expected to drive market growth.
Growing buzz around continuous bioprocessing may drive the adoption of single-use bioreactors over the coming years.
Applikon Biotechnology BV, Cellexus Ltd., and Celltainer Biotech B.V. are key market players.
| Estimated Size, 2025 | USD 450.2 billion |
|---|---|
| Projected Size, 2035 | USD 1,077.2 billion |
| CAGR (2025 to 2035) | 9.1% |
| Estimated Market Size (2024E) | USD 46.5 billion |
|---|---|
| Projected Market Value (2034F) | USD 161 billion |
| Value-based CAGR (2024 to 2034) | 13.3% |
| Market Size (2023) | USD 42.7 billion |
|---|---|
| Market Size (2033) | USD 80.8 billion |
| Market CAGR (2023 to 2033) | 6.6% |
| Market Value in 2021 | USD 51.0 Billion |
|---|---|
| Market Value in 2032 | USD 168.7 Billion |
| Market CAGR (2022 to 2032) | 12.3% |
Explore Life Science & Biotechnology Insights
View Reports
Single-use Bioreactors Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
